Skip to main content
. 2019 Dec 9;130(1):539–551. doi: 10.1172/JCI131958

Figure 1. Quadrivalent vaccine design and study strategy.

Figure 1

(A) Genetic organization of attenuated rVSV quadrivalent vaccine vectors. Vectors of the rVSV N4CT1-FiloGP design contained a filovirus GP gene(s) in position 1, an N gene translocation (N4), and a truncated G gene (CT1). (B) The rVSV N4ΔG-LASVGPC vector design contained the LASV GPC gene in position 1, an N gene translocation (N4), and a deletion of the VSV G gene. (C) Expression of the LASV GP in virus-infected cell lysates by Western blot analysis. (D) Flow chart showing the days of vaccination (triangles) and days of sampling for immunogenicity study (arrows). Day 28 samples were only taken from SUDV and MARV arms. *Day of challenge.